142 MARINE INGREDIENTS
(collagen, elastin and glycosaminoglycans) between the fibroblasts which ensures the skin’s structure and tone. When the deterioration and the repair of this network are imbalanced, wrinkles appear and the skin loses its firmness. Fucoidans protect this network by blocking the enzymes responsible for the deterioration of the extracellular matrix as well as the pro- inflammatory cytokines which damage the collagen.4,5
The anti-ageing active also acts
as a repairing agent by stimulating the metabolism of the fibroblasts and collagen synthesis. With these 2 synergistic actions, the anti-ageing active helps to reverse the signs of ageing by bringing back the skin’s structure and firmness.
In vitro tests The effect of the anti-ageing active on the fibroblasts’ proliferation and synthesis of collagen has been evaluated on human dermal fibroblasts. The anti-ageing active was tested at 2 concentrations: 0.15% and 1.5%. Untreated cells were used as negative control (CTR-).
Stimulating fibroblast proliferation Protocol Culture medium containing the tested product was added to the wells containing cells in the G0 phase of cell cycle. At the end of incubation period, the cell viability was evaluated and the increasing proliferating rate compared to untreated control cell culture.
Results
The data are reported as the percentage increase of cell proliferation after cells’ exposure to the test item, in respect to untreated cells. The treatment with the anti-ageing active has positively modulated cell proliferation in the considered experimental system. All recorded variations are significant vs negative control (CTR-). A significant increase in the proliferation of fibroblasts compared to the
60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0%
Figure 2: Chemical structure of Fucoreverse.
non-treated group of: +35.5% in the 0.15% dose; 51.1% in the 1.5% dose.
Stimulating type 1 collagen synthesis compared with the negative control Protocol The determination of collagen synthesis is carried out by quantitative dye-binding method. The chromogen agent used in the assay is Sirius Red. The collagen concentration is calculated by means of date interpolation on a standard curve obtained with know and increasing collagen concentrations. Results
The data are reported as the percentage increase of collagen synthesis after cells’ exposure to the test item respect untreated cells. The treatment with the anti-ageing active has positively modulated collagen synthesis in the considered experimental system. All recorded variations are significant vs negative control (CTR-). The anti-ageing active has a significant
+51.1% +35.5%
0% 0%
Untreated cells Fucoreverse™ proliferation Figure 3: Fibroblast proliferation relative to untreated cells. PERSONAL CARE EUROPE
45% 40% 35% 30% 25% 20% 15% 10% 5% 0%
0.15% 1.5%
stimulatory effect on collagen synthesis compared to the non-treated control group: + 23.7 % in the 0.15% dose; + 31.1 % in the 1.5% dose.
Clinical study Protocol
The aim of the study is to evaluate the safety of use, the cosmetic acceptability and the efficacy of the anti-ageing active. It is considered whether the product works on the wrinkles depth. In order to reach this goal, a clinical-intrumental study is carried out on 42 volunteers showing wrinkles on the crow’s foot area, divided in two groups according to the randomisation lists: group A received the active product whereas group B received placebo. Product efficacy is evaluated after 28 days of product use by means of non-invasive skin bioengineering technique to evaluate skin profilometry. The active product used contain 1.5% of the anti-ageing active.
+31.1% +23.7%
0% 0%
Untreated cells Fucoreverse™ concentration Figure 4: Collagen synthesis relative to untreated cells. April 2018
0.15%
1.5%
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184
